Posted by Michael Wonder on 10 Dec 2025
Biogen receives Health Canada authorisation for Zurzuvae (zuranolone), the first and only treatment indicated for adults with postpartum depression in Canada
9 December 2025 - Biogen Canada today announced that Health Canada has issued a Notice of Compliance for Zurzuvae (zuranolone) for the treatment of moderate or severe post-partum depression in adults following childbirth.
The approval of Zurzuvae is based on the NEST clinical development program, which included the ROBIN and SKYLARK studies.
